Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Expert Report on antibody drug conjugates in the management of urothelial cancer - ASCO GU 2022

Reporting from the ASCO Genitourinary Symposium 2022, Petros Grivas comments on data from studies that support further evaluation in urothelial cancer, in particular sacituzumab govitecan + pembrolizumab in the metastatic setting for platinum-refractory disease, nivolumab + trastuzumab deruxtecan in patients with HER2-expressing tumour, and single agent enfortumab vedotin in the neoadjuvant setting before radical cystectomy in patients who are cisplatin-ineligible.


  • 434 - TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.
  • 438 - Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).
  • 435 - Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.